Cancer, Lung Carcinoid Tumors


Article Author:
Faten Limaiem


Article Editor:
Jason Wallen


Editors In Chief:
Ishwarlal Jialal


Managing Editors:
Avais Raja
Orawan Chaigasame
Khalid Alsayouri
Kyle Blair
Radia Jamil
Erin Hughes
Patrick Le
Anoosh Zafar Gondal
Saad Nazir
William Gossman
Hassam Zulfiqar
Navid Mahabadi
Hussain Sajjad
Steve Bhimji
Muhammad Hashmi
John Shell
Matthew Varacallo
Heba Mahdy
Ahmad Malik
Sarosh Vaqar
Mark Pellegrini
James Hughes
Beenish Sohail
Hajira Basit
Phillip Hynes
Sandeep Sekhon


Updated:
11/12/2019 3:34:29 PM

Introduction

Pulmonary carcinoid tumors are uncommon neuroendocrine epithelial malignancies accounting for less than 1% of all lung cancers. They divide into two subcategories: typical carcinoids and atypical carcinoids. Typical carcinoids and atypical carcinoids are, respectively, low- and intermediate-grade neuroendocrine tumors. Approximately 80% of pulmonary carcinoids occur centrally, and 20% are peripheral.[1] All bronchial carcinoids are malignant and have the potential to metastasize.[2]

Etiology

The mechanisms of carcinoid tumor development and progression are not clear, but some cases are postulated to develop in the setting of proliferating pulmonary neuroendocrine cells via diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) and tumorlets.[3]

Epidemiology

Carcinoid tumors comprise less than 1% of primary lung cancers.[4] The mean age at presentation is about 50 years, but they can occur at any age from 5 to 90 years. Atypical carcinoids present approximately one decade later than typical carcinoids. About 8% develop in the second decade, making them the most common primary pulmonary tumor of childhood. The male to female distribution is equal. Typical carcinoids are not correlated to tobacco smoking, although reports of atypical carcinoids are more frequent in smokers.[5] Risk factors of carcinoids include having a family history of carcinoid tumors and carrying the MEN1 gene.[6]

Histopathology

Macroscopic findings:

Central carcinoid tumors are well-circumscribed, round to ovoid, and sessile or pedunculated. They often fill the bronchial lumen.[7] The tumors may grow between the cartilaginous plates into adjacent tissues. Carcinoids range in size from 0.5 to 9.5 cm. Atypical carcinoids are on average larger than typical carcinoids.[7]

Histopathology:

The growth patterns of carcinoid tumors suggest neuroendocrine differentiation. Organoid and trabecular patterns are most common; however, rosette formation, papillary growth, pseudo-glandular growth, and follicular growth may also be present. The tumor cells are usually uniform in appearance, with finely granular nuclear chromatin, inconspicuous nucleoli and moderate to abundant eosinophilic cytoplasm.[8] The stroma is classically highly vascularized, but extensive hyalinization, cartilage or bone formation may be encountered.  There are reports of stromal amyloid as well as prominent mucinous stroma. Typical carcinoids are carcinoid tumors with less than 2 mitoses per 2mm2 and lacking necrosis. Atypical carcinoid generally shows the same range of histological features as typical carcinoid. The defining features are 2 to 10 mitoses per 2mm2 and/or necrosis. Necrosis is usually punctate. Mitoses counting should be in the area of highest mitotic activity in the fields filled with many viable tumor cells as possible and should also be per 2mm2 rather than ten high-power fields.[8]

Immunohistochemistry:

Immunohistochemistry may be a necessity for diagnosis, particularly on small biopsies. An antibody panel including chromogranin A, synaptophysin (both with cytoplasmic labeling) and CD56 (mostly decorating cell membranes) is the recommendation. However, none of these markers distinguish typical carcinoid from atypical carcinoid. Most carcinoids are also reactive for pan-cytokeratin antibodies. Some peripheral tumors also stain with TTF1, which is less specific. The Ki67 labeling index is valuable in biopsy or cytology samples, particularly with crush artifact where the mitotic index is difficult to assess, to avoid misdiagnosing carcinoid tumors as high neuroendocrine carcinomas.[8]

History and Physical

The most common presenting symptoms of bronchopulmonary carcinoid tumors are:

  • Cough
  • Hemoptysis
  • Symptoms referable to the consequences of collapse or pneumonia distal to airway obstruction.[1] Sometimes the patients present with wheezing or even stridor.

Small carcinoids may be asymptomatic and only discovered, incidentally.

Most cases are endocrinologically silent at the clinical level. Clinical syndromes secondary to peptide production are uncommon, they include carcinoid syndrome, Cushing syndrome, and acromegaly.[1]

Evaluation

Biochemical evaluation:

Plasma chromogranin A measurement, blood count, electrolytes, liver, and kidney function are tests indicated in the diagnostic process and follow-up of carcinoids[9].

Specific tests are performed when symptoms suggesting hormonal secretion are present. They include[10]:

  • Urinary dU-5-hydroxy indol-acetic acid in patients with carcinoid syndrome
  • Serum cortisol, 24-hour urine free cortisol
  • ACTH level determination in patients with Cushing’s disease
  • Plasma GHRH and insulin growth factor (IGF)-I are indicated in patients with signs of acromegaly

Bronchoscopy:

Since lung carcinoids are usually centrally located and visible at endoscopic evaluation, bronchoscopy plays a significant role in their diagnosis.[11] Bronchoscopic evaluation and biopsy is the gold standard for the diagnosis of pulmonary carcinoids; however, there is a risk of hemorrhage. 

Radiological assessment:

Carcinoids can are detectable on a standard chest x-ray in 40% of the cases. However, the gold standard for radiological detection of lung carcinoids is CT scan. On both, chest x-ray and CT scan, the mass is usually well-defined, round, and sometimes slightly lobulated. Calcification can occur in central carcinoid tumors. When bronchial involvement is present, secondary distal effects include atelectasis, bronchiectasis, and, hyperlucency on CT scan.[12]

Fluorodeoxyglucose (FDG) positron emission tomography (PET) may distinguish carcinoid tumors from atypical carcinoids; this technique may be most helpful in discerning carcinoids from high-grade neuroendocrine tumors such as small cell or large cell neuroendocrine tumors.[13] Carcinoids exhibit a low-to-moderate activity on PET scanning.

Octreotide single-photon emission CT and other novel imaging techniques such as gallium-labeled somatostatin analogs may be more sensitive at the detection of lung carcinoids.[14] Imaging for somatostatin receptors using Indium-111-labeled-octreotide may increase the sensitivity for diagnosis, staging, and follow-up for recurrence.[15]

Treatment / Management

Surgery:

The treatment of choice for patients with lung carcinoids is surgical resection.[10] Extensive resections are necessary in the treatment of atypical carcinoids and cases of destruction of distal lung parenchyma. Lobectomy (sleeve or wedge resection) is the surgical technique of choice. Bronchoplastic procedures are often required since carcinoids often arise from main bronchi or lobar bronchi. A wedge resection is favored in peripheral carcinoids and is often sufficient.[1]

Adjuvant therapy:

There is no consensus on adjuvant therapy in pulmonary carcinoids.[1] The National Comprehensive Cancer Network guidelines recommend adjuvant cisplatin and etoposide with or without radiation in stage III atypical carcinoids.[1] The European Neuroendocrine Tumor Society advocates adjuvant treatment in atypical carcinoids with positive lymph nodes, but no adjuvant therapy for typical carcinoids.[1]

Differential Diagnosis

The differential diagnoses of pulmonary carcinoids include[8]:

  • Metastatic carcinoids from elsewhere especially those originating from the gastrointestinal tract
  • Small cell lung carcinoma
  • Salivary gland-type tumors
  • Metastases of lobular breast carcinoma, paraganglioma, and glomangioma
  • Tumorlets

Staging

Typical carcinoids:

In pulmonary carcinoid tumors, the classification system designates typical carcinoids as low grade.[16] Most typical carcinoids are stage 1a.[16]

Atypical carcinoids:

In pulmonary carcinoid tumors, the classification system designates atypical carcinoids as intermediate grade. Atypical carcinoids are usually at a higher stage at presentation than typical carcinoids.[16]

Enhancing Healthcare Team Outcomes

The distinction between atypical carcinoid and typical carcinoid is the most important prognostic factor. Atypical carcinoid has a worse prognosis than typical carcinoid. Atypical carcinoids are more likely to metastasize than typical carcinoids. Typical carcinoid tumors metastasize to hilar nodes in 10% to 15%.[17] Distant metastases are less common. They occur in fewer than 3% of patients and involve the liver, lung, brain, adrenal or bone.[18] For atypical carcinoid tumors, metastatic disease is present in 20% of patients.[19] Age and nodal involvement are poor prognostic factors in patients with atypical carcinoids.[19] Five-year survival rates for patients with typical carcinoids and atypical carcinoids are approximately 90% and 60% respectively.[1]


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Cancer, Lung Carcinoid Tumors - Questions

Take a quiz of the questions on this article.

Take Quiz
A 53-year-old nonsmoker presents with hemoptysis. Work-up reveals a mass on a CT scan. Bronchoscopy is done and a 2 cm mass is seen at the origin of the right main bronchus. The patient denies weight loss or any other symptoms. The tumor is most likely which of the following?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A patient with a 3-cm unknown lung mass first undergoes a mediastinoscopy. The frozen sections reveal carcinoid tumor. What is the next step in his management?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following feature of a carcinoid is correct?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following statements regarding pulmonary carcinoid tumors is true?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following statements regarding pulmonary atypical carcinoids is true?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 28-year-old-male presented with a two-year history of cough, hemoptysis, and shortness of breath. Chest x-ray showed a left hilar opacity. Chest CT scan revealed an oval mass in the left upper lobe obstructing the left upper lobar bronchus with a collapse of the upper lobe segments. The patient underwent a left upper lobectomy with regional lymph node dissection through a left posterolateral thoracotomy. Histopathological examination of the surgical specimen revealed a tumor proliferation arranged in a trabecular pattern with a fine vascular stroma. The tumor cells were uniform with finely granular nuclear chromatin and abundant eosinophilic cytoplasm. There was one mitosis per 2 mm2 and no foci of necrosis. Immunohistochemically, the tumor cells were positive for chromogranin A, synaptophysin, and CD56. The Ki-67 index was about 1%. What is the most likely diagnosis?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Cancer, Lung Carcinoid Tumors - References

References

Saber M,Ismail Y,Alieldin N,Loay I,El Zawahry M, Neuroendocrine tumors of the lung: A five-year retrospective experience of Egyptian NCI (2010-2014). Journal of the Egyptian National Cancer Institute. 2018 Dec;     [PubMed]
Rekhtman N, Neuroendocrine tumors of the lung: an update. Archives of pathology     [PubMed]
Hemminki K,Li X, Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer. 2001 Oct 15;     [PubMed]
Quaedvlieg PF,Visser O,Lamers CB,Janssen-Heijen ML,Taal BG, Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Annals of oncology : official journal of the European Society for Medical Oncology. 2001 Sep;     [PubMed]
Yao JC,Hassan M,Phan A,Dagohoy C,Leary C,Mares JE,Abdalla EK,Fleming JB,Vauthey JN,Rashid A,Evans DB, One hundred years after     [PubMed]
Swarts DR,Ramaekers FC,Speel EJ, Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities. Biochimica et biophysica acta. 2012 Dec;     [PubMed]
Caplin ME,Baudin E,Ferolla P,Filosso P,Garcia-Yuste M,Lim E,Oberg K,Pelosi G,Perren A,Rossi RE,Travis WD, Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Aug;     [PubMed]
Gosain R,Mukherjee S,Yendamuri SS,Iyer R, Management of Typical and Atypical Pulmonary Carcinoids Based on Different Established Guidelines. Cancers. 2018 Dec 12;     [PubMed]
Ferolla P, Medical treatment of advanced thoracic neuroendocrine tumors. Thoracic surgery clinics. 2014 Aug;     [PubMed]
Queiroz RM,Santana DBF,Nastri Filho R,Landell GAM,Félix PR,Valentin MVN, Endobronchial carcinoid tumor: Radiological findings of a clinical case. Revista da Associacao Medica Brasileira (1992). 2018 Jan;     [PubMed]
Erasmus JJ,McAdams HP,Patz EF Jr,Coleman RE,Ahuja V,Goodman PC, Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR. American journal of roentgenology. 1998 May;     [PubMed]
Venkitaraman B,Karunanithi S,Kumar A,Khilnani GC,Kumar R, Role of 68Ga-DOTATOC PET/CT in initial evaluation of patients with suspected bronchopulmonary carcinoid. European journal of nuclear medicine and molecular imaging. 2014 May;     [PubMed]
Daniels CE,Lowe VJ,Aubry MC,Allen MS,Jett JR, The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest. 2007 Jan;     [PubMed]
Naalsund A,Rostad H,Strøm EH,Lund MB,Strand TE, Carcinoid lung tumors--incidence, treatment and outcomes: a population-based study. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2011 Apr;     [PubMed]
Crocetti E,Paci E, Malignant carcinoids in the USA, SEER 1992-1999. An epidemiological study with 6830 cases. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP). 2003 Jun;     [PubMed]
Steuer CE,Behera M,Kim S,Chen Z,Saba NF,Pillai RN,Owonikoko TK,Khuri FR,Ramalingam SS, Atypical carcinoid tumor of the lung: a surveillance, epidemiology, and end results database analysis. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Mar;     [PubMed]
Filosso PL,Rena O,Donati G,Casadio C,Ruffini E,Papalia E,Oliaro A,Maggi G, Bronchial carcinoid tumors: surgical management and long-term outcome. The Journal of thoracic and cardiovascular surgery. 2002 Feb;     [PubMed]
Rosado de Christenson ML,Abbott GF,Kirejczyk WM,Galvin JR,Travis WD, Thoracic carcinoids: radiologic-pathologic correlation. Radiographics : a review publication of the Radiological Society of North America, Inc. 1999 May-Jun;     [PubMed]
Lim E,Yap YK,De Stavola BL,Nicholson AG,Goldstraw P, The impact of stage and cell type on the prognosis of pulmonary neuroendocrine tumors. The Journal of thoracic and cardiovascular surgery. 2005 Oct;     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of Pathology-Chemistry. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for Pathology-Chemistry, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in Pathology-Chemistry, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of Pathology-Chemistry. When it is time for the Pathology-Chemistry board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study Pathology-Chemistry.